STANDARD CHEMICAL & PHARMACEUTICAL CO. LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 73.8 TWD | -0.14% |
|
+3.22% | +11.99% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2023 | 2024 |
|---|---|---|---|---|---|
| Capitalization 1 | 6,022 | 6,737 | 7,702 | 11,776 | 13,188 |
| Enterprise Value (EV) 1 | 6,022 | 6,737 | 7,702 | 11,776 | 13,188 |
| P/E ratio | - | - | - | 14.1 x | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 1.53 x | 1.56 x | 1.67 x | - | 1.94 x |
| EV / Revenue | 1.53 x | 1.56 x | 1.67 x | - | 1.94 x |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | 11.8 x | 12.6 x | - | 14.5 x |
| FCF Yield | - | 8.46% | 7.97% | - | 6.89% |
| Price to Book | - | - | - | - | 2.46 x |
| Nbr of stocks (in thousands) | 178,696 | 178,696 | 178,696 | 178,696 | 178,696 |
| Reference price 2 | 33.70 | 37.70 | 43.10 | 65.90 | 73.80 |
| Announcement Date | 20-03-26 | 21-03-17 | 22-03-16 | 24-03-01 | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2023 | 2024 |
|---|---|---|---|---|---|
| Net sales 1 | 3,937 | 4,305 | 4,604 | - | 6,803 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | 515.8 | 706.6 | 876.7 | - | 1,412 |
| Operating Margin | 13.1% | 16.41% | 19.04% | - | 20.76% |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | - | - | - | 834.9 | - |
| Net margin | - | - | - | - | - |
| EPS | - | - | - | 4.670 | - |
| Free Cash Flow 1 | - | 570.1 | 613.6 | - | 909 |
| FCF margin | - | 13.24% | 13.33% | - | 13.36% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 20-03-26 | 21-03-17 | 22-03-16 | 24-03-01 | - |
1TWD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,237 | 1,481 | 1,493 | 1,509 | 1,646 | 1,614 | 1,650 | 1,750 | 1,790 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 205.3 | 302.2 | 335.8 | 295.9 | 320.8 | 340.7 | 329 | 367 | 377 |
| Operating Margin | 16.59% | 20.4% | 22.49% | 19.61% | 19.49% | 21.11% | 19.94% | 20.97% | 21.06% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 22-05-11 | 22-08-03 | 23-05-10 | 23-08-10 | 23-11-09 | 24-05-08 | - | - | - |
1TWD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2023 | 2024 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | 570 | 614 | - | 909 |
| ROE (net income / shareholders' equity) | - | 13.6% | 17% | - | 10.7% |
| ROA (Net income/ Total Assets) | - | 7.5% | 8.24% | - | 7.9% |
| Assets | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | - | 30.00 |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 353 | 213 | - | 300 |
| Capex / Sales | - | 8.19% | 4.64% | - | 4.41% |
| Announcement Date | 20-03-26 | 21-03-17 | 22-03-16 | 24-03-01 | - |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
73.8
TWD
Average target price
80
TWD
Spread / Average Target
+8.40%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +11.99% | 405M | |
| +55.19% | 815B | |
| +46.54% | 654B | |
| -6.09% | 354B | |
| +21.92% | 337B | |
| +19.08% | 247B | |
| +3.84% | 229B | |
| +13.93% | 219B | |
| +10.86% | 171B | |
| -2.78% | 159B |
- Stock Market
- Equities
- 1720 Stock
- Financials Standard Chemical & Pharmaceutical Co. Ltd.
